Edap TMS SA signed a €36 million (US$42 million) multi-tranche credit facility with the European Investment Bank, with the first tranche of €11 million expected to be disbursed in early November. The funds will be used to strengthen the company’s balance sheet to support the continued expansion of its Focal One high-intensity focused ultrasound technology in focal therapy and accelerate the development of new clinical indications.

Radiopharm Theranostics Ltd. completed a AU$35 million (US$22.77 million) placement to advance six of its radiopharmaceutical candidates for both diagnostic and therapeutic uses. The funds raised will go toward clinical trials, drug manufacturing and working capital to extend Radiopharm’s funding runway into 2027.

Comind Technologies Ltd. secured $60 million in funding for its optical neuromonitoring device which non-invasively measures key physiological parameters of the brain to provide critical information on its health. The technology could significantly improve the way the brain is monitored by addressing key challenges of current methods such as inaccuracy, invasiveness and limited availability when needed.

Oura Health Oy raised more than $900 million in a series E funding round to fuel global expansion of its popular smart ring and development of new health technologies. The new infusion brings the company’s total funds raised to date to $1.5 billion and implies a corporate valuation of about $11 billion, Oura said.

Who knew? In addition to adopting a new name, Kneu Health Ltd. recently raised $5.6 million in a seed funding round for its smart-phone-based platform which helps to monitor neurological disorders to enable timely intervention. The funds secured will be used to expand commercial operations in the U.S., scale deployments for Parkinson's disease and advance the monitoring capabilities of the platform for dementia.